Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894115 | 0.84 | ELANE (0.41) | ELANECYP4F2CYP4A11TDP1MEN1 | |
| SCHEMBL10087895 | 0.83 | ELANE (0.43) | ELANECYP4F2CYP4A11TDP1MEN1 | |
| SCHEMBL19018787 | 0.80 | ELANE (0.41) | ELANECYP4F2CYP4A11TDP1MEN1 | |
| SCHEMBL6892271 | 0.80 | ELANE (0.41) | ELANECYP4F2CYP4A11TDP1MEN1 | |
| SCHEMBL11446926 | 0.79 | — | — | |
| SCHEMBL12514347 | 0.78 | ELANE (0.37) | ELANECYP4F2CYP4A11LMNAHSD17B10 | |
| SCHEMBL26932887 | 0.78 | MMP8 (0.30) | — | |
| SCHEMBL13649170 | 0.77 | ELANE (0.39) | ELANECYP4F2CYP4A11TDP1LMNA | |
| SCHEMBL26431688 | 0.76 | PRKCA (0.47) | ELANECYP4F2CYP4A11TDP1MEN1 | |
| SCHEMBL12120737 | 0.76 | CYP4F2 (0.42) | ELANECYP4F2CYP4A11TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629383-B2 | Double esters | DRUG DISCOVERY LABORATORY AS (NO) | 2009-12-08 | — | — | US | disclosed |
| EP-1448508-B1 | DOUBLE ESTERS | DRUG DISCOVERY LAB AS (NO) | 2009-09-23 | — | — | EP | disclosed |
| CN-100516018-C | Double esters | PHOTOCURE ASA (NO) | 2009-07-22 | — | — | CN | disclosed |
| US-20050203181-A1 | Double esters | DRUG DISCOVERY LABORATORY AS (NO) | 2005-09-15 | — | — | US | disclosed |
| CN-1589254-A | Double esters | PHOTOCURE ASA (NO) | 2005-03-02 | — | — | CN | disclosed |
| EP-1448508-A1 | DOUBLE ESTERS | Photocure ASA (NO) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045893-A1 | DOUBLE ESTERS | PHOTOCURE ASA (NO) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203181-A1 | Double esters | ACACA, CES1, ACACB | ELANE 120/4885CYP4F2 185/4885CYP4A11 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.